Share on StockTwits

C.R. Bard (NYSE:BCR) reached a new 52-week high during trading on Monday , Analyst Ratings Net reports. The stock traded as high as $153.00 and last traded at $152.74, with a volume of 561,322 shares trading hands. The stock had previously closed at $148.85.

A number of research firms have recently commented on BCR. Analysts at Zacks reiterated a “neutral” rating on shares of C.R. Bard in a research note on Monday. They now have a $156.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of C.R. Bard in a research note on Friday. They now have a $170.00 price target on the stock, up previously from $155.00. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of C.R. Bard in a research note on Friday. They now have a $145.00 price target on the stock, up previously from $139.00. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and six have assigned a buy rating to the company. C.R. Bard has an average rating of “Hold” and a consensus target price of $144.25.

The stock’s 50-day moving average is $143.6 and its 200-day moving average is $141.5. The company has a market cap of $11.429 billion and a P/E ratio of 15.17.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Thursday, July 24th. The company reported $2.06 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.01 by $0.05. The company had revenue of $827.10 million for the quarter, compared to the consensus estimate of $814.58 million. During the same quarter in the prior year, the company posted $1.42 earnings per share. The company’s quarterly revenue was up 8.8% on a year-over-year basis. Analysts expect that C.R. Bard will post $8.28 EPS for the current fiscal year.

C. R. Bard, Inc (NYSE:BCR) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.